Kris Vaddi

9.9k total citations · 2 hit papers
68 papers, 3.7k citations indexed

About

Kris Vaddi is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Kris Vaddi has authored 68 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 23 papers in Genetics and 21 papers in Hematology. Recurrent topics in Kris Vaddi's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers), Cancer-related gene regulation (19 papers) and Acute Myeloid Leukemia Research (10 papers). Kris Vaddi is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers), Cancer-related gene regulation (19 papers) and Acute Myeloid Leukemia Research (10 papers). Kris Vaddi collaborates with scholars based in United States, Italy and Spain. Kris Vaddi's co-authors include Anthony W. Ferrante, Jacob E. Lemieux, Israel Charo, Reid Huber, Sarah Slaymaker, Rudolph L. Leibel, Deborah Hunter, Stuart P. Weisberg, Jordan S. Fridman and Srđan Verstovšek and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Kris Vaddi

65 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CCR2 modulates inflammatory and metabolic effects of high-fat feeding

2005 1.2k citations Stuart P. Weisberg, Deborah Hunter et al. Journal of Clinical Investigation profile →
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

2010 847 citations Srđan Verstovšek, Hagop M. Kantarjian et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kris Vaddi United States	26	1.5k	1.1k	955	909	739	68	3.7k
Victor J. Wroblewski United States	30	3.2k 2.2×	612 0.5×	487 0.5×	812 0.9×	603 0.8×	60	5.2k
Remigio Moratti Italy	26	2.1k 1.5×	794 0.7×	460 0.5×	716 0.8×	219 0.3×	80	3.5k
Julie A. Vrana United States	34	2.6k 1.7×	343 0.3×	343 0.4×	358 0.4×	395 0.5×	69	3.6k
Chunhua Dai United States	37	1.6k 1.1×	617 0.6×	253 0.3×	653 0.7×	473 0.6×	88	4.2k
Catherine Meyer‐Schwesinger Germany	37	1.3k 0.9×	267 0.2×	558 0.6×	260 0.3×	1.3k 1.8×	93	4.6k
Takashi Murate Japan	32	2.0k 1.4×	504 0.5×	245 0.3×	944 1.0×	426 0.6×	137	3.5k
Coleen A. McNamara United States	42	2.2k 1.5×	211 0.2×	787 0.8×	521 0.6×	2.0k 2.7×	114	5.3k
Bahjat Al‐Ani Saudi Arabia	30	816 0.6×	1.1k 1.0×	209 0.2×	1.4k 1.5×	646 0.9×	94	3.4k
Carrie L. Welch United States	33	2.8k 1.9×	238 0.2×	1.0k 1.1×	308 0.3×	1.8k 2.5×	64	6.3k
Bruce A. Hug United States	23	1.6k 1.1×	334 0.3×	235 0.2×	601 0.7×	590 0.8×	47	3.6k

Countries citing papers authored by Kris Vaddi

Since Specialization

Citations

This map shows the geographic impact of Kris Vaddi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kris Vaddi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kris Vaddi more than expected).

Fields of papers citing papers by Kris Vaddi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kris Vaddi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kris Vaddi. The network helps show where Kris Vaddi may publish in the future.

Co-authorship network of co-authors of Kris Vaddi

This figure shows the co-authorship network connecting the top 25 collaborators of Kris Vaddi. A scholar is included among the top collaborators of Kris Vaddi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kris Vaddi. Kris Vaddi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mao, Charlene, Peggy Scherle, Neha Bhagwat, et al.. (2024). Targeting PRMT5 in Primary Hemophagocytic Lymphohistiocytosis: A Novel Therapeutic Approach Using a Perforin-Deficient Mouse Model. Blood. 144(Supplement 1). 809–809.

Vaddi, Kris, et al.. (2023). Abstract 6270: Combination therapy with selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1)-deficient cancers. Cancer Research. 83(7_Supplement). 6270–6270. 1 indexed citations

Zitzer, Nina C., Yandi Gao, Hannah Choe, et al.. (2020). PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease. JCI Insight. 5(8). 27 indexed citations

Padron, Eric, Amy E. DeZern, Marcio Andrade‐Campos, et al.. (2016). A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clinical Cancer Research. 22(15). 3746–3754. 62 indexed citations

Vaddi, Kris, et al.. (2016). Ruxolitinib: a targeted treatment option for patients with polycythemia vera. SHILAP Revista de lepidopterología. 1 indexed citations

Li, Jun, Eian Caulder, Margaret Favata, et al.. (2015). Abstract 779: Blockade of the IL-6/JAK/STAT3 signaling pathway inhibits pancreatic tumor cell growth in 3D spheroid cultures and in xenograft models. Cancer Research. 75(15_Supplement). 779–779. 1 indexed citations

Verstovšek, Srđan, et al.. (2014). Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. International Journal of General Medicine. 7. 89–89. 72 indexed citations

Vaddi, Kris, Nicholas J. Sarlis, & Vikas Gupta. (2012). Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opinion on Pharmacotherapy. 13(16). 2397–2407. 34 indexed citations

Fridman, Jordan S., Peggy Scherle, Robert J. Collins, et al.. (2011). Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation. Journal of Investigative Dermatology. 131(9). 1838–1844. 88 indexed citations

10.

Guglielmelli, Paola, Lisa Pieri, Roberta Zini, et al.. (2011). Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,. Blood. 118(21). 3852–3852. 1 indexed citations

11.

Li, Jun, Margaret Favata, Eian Caulder, et al.. (2010). INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support. Neoplasia. 12(1). 28–38. 62 indexed citations

12.

Verstovšek, Srđan, Hagop M. Kantarjian, Ruben A. Mesa, et al.. (2010). Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. New England Journal of Medicine. 363(12). 1117–1127. 847 indexed citations breakdown →

13.

Liu, Phillip C.C., Eian Caulder, Jun Li, et al.. (2009). Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity. Clinical Cancer Research. 15(22). 6891–6900. 15 indexed citations

14.

Fridman, Jordan S., Eian Caulder, Xiaoming Wen, et al.. (2009). Abstract #2848: Small molecule inhibitors of JAK1/2 improve physiological and functional measures of cancer-associated cachexia. Cancer Research. 69. 2848–2848. 1 indexed citations

15.

Burns, David, Chunhong He, Yanlong Li, et al.. (2007). Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1′ permutations. Bioorganic & Medicinal Chemistry Letters. 18(2). 560–564. 13 indexed citations

16.

Liu, Xiangdong, Jordan S. Fridman, Qian Wang, et al.. (2006). Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biology & Therapy. 5(6). 648–656. 45 indexed citations

17.

Scherle, Peggy, Jordan S. Fridman, Wenqing Yao, et al.. (2006). Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Journal of Clinical Oncology. 24(18_suppl). 13021–13021. 7 indexed citations

18.

Weisberg, Stuart P., Deborah Hunter, Reid Huber, et al.. (2005). CCR2 modulates inflammatory and metabolic effects of high-fat feeding. Journal of Clinical Investigation. 116(1). 115–124. 1226 indexed citations breakdown →

19.

Newton, Robert, Kimberly A. Solomon, Maryanne Covington, et al.. (2001). Biology of TACE inhibition. Annals of the Rheumatic Diseases. 60. iii25–iii32. 80 indexed citations

20.

Devalaraja, Madhav N., Craig J. McClain, Shirish Barve, Kris Vaddi, & Daniell B. Hill. (1999). INCREASED MONOCYTE MCP-1 PRODUCTION IN ACUTE ALCOHOLIC HEPATITIS. Cytokine. 11(11). 875–881. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact